- Home
- INZY vs CHRS Comparison
INZY vs CHRS Comparison
Compare INZY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- CHRS
- Stock Information
- Founded
- INZY 2015
- CHRS 2010
- Country
- INZY United States
- CHRS United States
- Employees
- INZY N/A
- CHRS 235
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INZY Health Care
- CHRS Health Care
- Exchange
- INZY Nasdaq
- CHRS Nasdaq
- Market Cap
- INZY 188.2M
- CHRS 134.4M
- IPO Year
- INZY 2020
- CHRS 2014
- Fundamental
- Price
- INZY $1.36
- CHRS $1.16
- Analyst Decision
- INZY Strong Buy
- CHRS Strong Buy
- Analyst Count
- INZY 8
- CHRS 4
- Target Price
- INZY $17.75
- CHRS $5.38
- AVG Volume (30 Days)
- INZY 1.0M
- CHRS 2.4M
- Earning Date
- INZY 03-11-2025
- CHRS 03-12-2025
- Dividend Yield
- INZY N/A
- CHRS N/A
- EPS Growth
- INZY N/A
- CHRS N/A
- EPS
- INZY N/A
- CHRS N/A
- Revenue
- INZY N/A
- CHRS $304,340,000.00
- Revenue This Year
- INZY N/A
- CHRS $2.47
- Revenue Next Year
- INZY N/A
- CHRS N/A
- P/E Ratio
- INZY N/A
- CHRS N/A
- Revenue Growth
- INZY N/A
- CHRS 44.19
- 52 Week Low
- INZY $1.24
- CHRS $0.66
- 52 Week High
- INZY $7.80
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- INZY 29.28
- CHRS 38.01
- Support Level
- INZY $1.35
- CHRS $1.03
- Resistance Level
- INZY $1.62
- CHRS $1.39
- Average True Range (ATR)
- INZY 0.13
- CHRS 0.14
- MACD
- INZY 0.04
- CHRS -0.03
- Stochastic Oscillator
- INZY 32.89
- CHRS 14.04
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.